SCHEMBL3552839

SCHEMBL3552839

CCOC(=O)C1CNCC1c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.76
PKM P14618 1/20 0.76
TSHR P16473 3/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
BACE1 P56817 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 1/20 0.45
DHFR P00374 1/20 0.45
LMNA P02545 1/20 0.44
TRPC5 Q9UL62 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26818738 1.00 MAPT (0.76) MAPTPKMTSHRMEN1KMT2A
SCHEMBL7887174 1.00 MAPT (0.76) MAPTPKMTSHRMEN1KMT2A
Hydrochloric Acid SCHEMBL5839304 0.99 MAPT (0.78) MAPTPKMTSHRMEN1KMT2A
SCHEMBL1105979 0.87 MAPT (0.97) MAPTPKMTSHRMEN1KMT2A
SCHEMBL19483128 0.87 MAPT (0.79) MAPTPKMTSHRMEN1KMT2A
SCHEMBL3209495 0.87 MAPT (0.97) MAPTPKMTSHRMEN1KMT2A
SCHEMBL28660767 0.87 MAPT (0.97) MAPTPKMTSHRMEN1KMT2A
SCHEMBL1095808 0.87 MAPT (0.97) MAPTPKMTSHRMEN1KMT2A
SCHEMBL3007095 0.87 MAPT (0.97) MAPTPKMTSHRMEN1KMT2A
SCHEMBL6029174 0.87 MAPT (0.79) MAPTPKMTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 MAPT 3715/4885PKM 1119/4885TSHR 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.